A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (NCT06667908)
A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Who can join: Review the eligibility criteria below.
Location: Moores Cancer Center at UC San Diego Health — La Jolla, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (43 Sites)
Showing the first 25 of 43 sites.
- Moores Cancer Center at UC San Diego Health — La Jolla, California
- University of Connecticut Health Center — Farmington, Connecticut
- Yale University — New Haven, Connecticut
- University of Miami — Miami, Florida
- Orlando Health Cancer Institute — Orlando, Florida
- Emory University Winship Cancer Institute — Atlanta, Georgia
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Washington University in St Louis — St Louis, Missouri
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- NYU Langone Health — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- FirstHealth of the Carolinas — Pinehurst, North Carolina
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Oregon Health And Science University — Portland, Oregon
- University of Pennsylvania — Philadelphia, Pennsylvania
- MD Anderson Cancer Center — Houston, Texas
- University of Vermont Medical Center — Burlington, Vermont
- Royal Brisbane and Women's Hospital — Herston,
- Sir Charles Gairdner Hospital — Nedlands,
- Macquarie University — North Ryde,
- Royal Melbourne Hospital — Parkville,
- Fundacao Pio XII — Barretos,
- Sociedade Beneficente de Senhoras Hospital Sirio Libanes — São Paulo,
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein — São Paulo,
📞 Contact the Study Coordinator
Phone: (844) 434-4210
Email: Participate-In-This-Study1@its.jnj.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.